Please login to the form below

Not currently logged in
Email:
Password:

Eli Lilly increases Chinese sales by 26 per cent

Eli Lilly says its has grown sales of its pharmaceutical products in China by 26 per cent, compared with sales over a year ago, with 16 per cent growth for the pharmaceutical industry in the region as a whole

US-based pharmaceutical company Eli Lilly has said it has grown sales of its pharmaceutical products in China by 26 per cent, compared with sales over a year ago, with 16 per cent growth for the pharmaceutical industry in the region as a whole.

The company added that it expected to become the tenth largest company in the global pharmaceutical market by 2010. China is expected to become the seventh largest pharmaceutical market in 2012 and the second largest in 2020.

Lilly says it will introduce five drugs to the Chinese market in 2007 and an additional fifteen drugs over the next five years. The company signed an agreement with Hutchison Whampao, a drug development unit owned by Li Ka-shing, for the development of western drugs for treating cancer and inflammation.

18th September 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...